. GC-MS, m/z calculated 250.1, experimental, 250.1. (Yield: 78%) . This compound is synthesized using the same procedure of 1-(dibenzo[b,d] thiophen-4-yl)-1H-imidazole with 1H-benzo [d] imidazole in the place of 1H-imidazole. 1 H NMR (CDCl 3 , 400 MHz). δ ppm: 8. 3 H), 7.97 (d, J=8 Hz, 1 H), 1 H), J=8 Hz, 1 H), 3 H), 3 H) . 13 C NMR (CDCl 3 , 101 MHz). δ ppm: 143.73, 142.31, 139.13, 138.18, 136.51, 135.28, 133.67, 131.08, 127.69, 125.57, 125.01, 124.13, 123.62, 123.00, 122.95, 122.06, 121.79, 120.73, 110 .97.
1-(dibenzo[b,d]thiophen-4-yl)-1H-benzo[d]imidazole

1-(dibenzo[b,d]thiophen-2-yl)-1H-imidazole (Yield: 77%
). This compound is synthesized using the same procedure of 1-(dibenzo [b,d] thiophen-4-yl)-1H-imidazole with 2-bromodibenzo[b,d] thiophene in the place of 4-bromodibenzo [b,d] 04, 137.07, 136.67, 136.31, 135.15, 134.92, 130.36, 128.12, 125.29, 124.74, 123.66, 123.11, 120.19, 118.87, 114.16 . (Yield: 93%) . 15 g hydrogen peroxide (30 wt%) was slowly dropped into 30 mL glacial acetic acid solution of 1-(dibenzo[b,d] thiophen-4-yl)-1H-imidazole (14 mmol) at 0 o C. After the addition, the temperature is raised to room temperature and the mixture solution are still kept stirring until the starting materials are almost consumed (TLC detection). The mixture solution was neutralized with 10wt% aq. NaHCO 3 solution. Then, the solution was extracted with dichloromethane and the organic phase are dried with anhydrous Na 2 SO 4 . The concentrated organic phase is purified using silica gel column chromatography with an eluent solution of dichloromethane/petroleum ether and the ideal product is received as white powder. Notice. A few amount of 4-(1H-imidazol-1-yl)dibenzo [b,d] thiophene 5,5-dioxide (1c) was also eluted out from the silica gel column and collected before the 4-(1H-imidazol-1-yl)dibenzo [b,d] thiophene 5-oxide. 1 H NMR (CDCl 3 , 400 MHz). δ ppm: 8.12 (s, 1 H), 8.00 (d, J=7.6 Hz, 1 H), 2 H), 7.75 (t, J=8 Hz, 1 H), 2 H), 7.60 (m, 1 H), 7.43 (dd, J=8, 0.8 Hz, 1 H), 7.33 (s, 1 H) . 13 C NMR (CDCl 3 , 101 MHz). δ ppm: 144.65, 140.12, 138.47, 138.09, 136.31, 134.38, 132.84, 130.74, 130.51, 127.53, 125.24, 122.27, 121.21, 121.14 : 144.74, 140.71, 140.49, 136.06, 134.60, 133.08, 130.78, 127.74, 126.99, 125.31, 124.90, 122.69, 122.48, 119.60 02, 139.50, 135.83, 135.58, 132.85, 131.30, 130.53, 129.27, 127.80, 122.24, 121.99, 118.07, 114.51. Compound 1a (Yield:95%). 5 mmol (bromomethyl)benzene was added in to 20 mL acetonitrile solution of compound 1c (1 mmol) and the mixture solution was stirred for 24 hours under argon atmosphere at room temperature. And then, removing CH 3 CN from the mixture solution under vacuum and adding methanol and 5 mmol KI to the residues, which was followed by stirring for another 12 hours at room temperature. Then, the solvent was removed by rotary evaporator. The inorganic salt in the residual oil was removed by extraction and the organic phase was collected together and dried over anhydrous Na 2 SO 4 . After the filtration and concentrated under reduced pressure, the crude product was purified by recrystallization with nhexane/methanol. 1 136.52, 136.36, 135.35, 134.20, 133.19, 132.06, 131.33, 130.34, S4 129.43, 129.10, 129.06, 128.95, 128.32, 125.13, 125.08, 123.61, 123.22, 122 : 138.17, 136.45, 136.23, 135.24, 133.18, 131.95, 131.05, 130.29, 129.32, 128.84, 124.93, 124.28, 124.23, 123.48, 122.18, 36.36 .
4-(1H-imidazol-1-yl)dibenzo[b,d]thiophene 5-oxide
Compound 1c (Yield: 98%).15 g hydrogen peroxide (30 wt%) was slowly dropped to 30 mL glacial acetic acid solution of 4-(1H-imidazol-1-yl)dibenzo [b,d] thiophene 5-oxide (10 mmol) at 0 °C. After the addition, the temperature is raised to room temperature and the mixture solution are still kept stirring until the starting materials S5 are almost consumed (TLC detection, new product was detected upon the original material in the TLC plate). The mixture solution was neutralized with 10wt% aq. NaHCO 3 solution. Then, the solution was extracted with dichloromethane and the organic phase are dried with anhydrous Na 2 SO 4 . The concentrated organic phase is purified using silica gel column chromatography with an eluent solution of dichloromethane/petroleum ether and the ideal product is received as white powder. 1 03, 137.03, 136.83, 135.84, 133.74, 132.55, 131.72, 130.94, 129.90, 129.43, 125.53, 124.99, 124.08, 123.41, 122.78, 45.57, 15.45. Compound 1e (Yield: 96%). This compound was synthesized using the same procedure of compound 1b just substituting the starting material of compound 1c with 4-(1H-imidazol-1-yl)dibenzo [b,d] : 144.13, 139.46, 139.33, 138.04, 135.84, 135.15, 134.44, 133.54, 130.96, 127.78, 126.84, 124.73, 124.65, 123.63, 123.55, 36.46 : 143.26, 137.83, 135.13, 134.56, 134.21, 133.14, 131.27, 130.20, 128.10, 124.50, 123.87, 122.33, 121.91, 121.54, 120.46, 110.66. Compound 2b (Yield: 99%). This compound was synthesized using the same procedure of 1e just substituting the starting material of 4-( 95, 144.27, 141.56, 140.05, 136.43, 135.74, 133.87, 132.42, 132.03, 131.29, 128.81, 128.15, 127.82, 125.85, 123.95, 114.58, 114.50, 104.99, 34.37. Compound 3a (Yield: 99%). 5 mmol iodomethane was added into 10 mL acetonitrile solution of compound 3b (1 mmol) and the mixture solution was stirred for overnight at room temperature under argon atmosphere. Then, there is a large amount of precipitate in the solution. After filtration and the precipitate was washed with THF and n-hexane and dried under vacuum. Compound 3a was then received as white powder finally. 1 88, 137.88, 137.63, 137.11, 135.44, 133.65, 132.54, 129.93, 125.18, 124.65, 124.43, 123.62, 122.85, 121.51, 116.90, 36.88 .
Cellular thermal shift assay
Cellular thermal shift assay was performed to monitor the target engagement of compounds in HeLa cells. Briefly, cell lysates from 2×10 6 HeLa cells were collected, diluted in PBS and separated in same aliquots. Each aliquot was treated with 1a (10 µM) or DMSO. 30 min after incubation at room temperature, the complex-treated lysates were divided into 50 µl in each of tubes and heated individually at different temperatures (Veriti thermal cycler, Applied Biosystems/Life Technologies). The heated lysates were centrifuged and the supernatants were analyzed by SDS-PAGE followed by immunoblotting analysis by probing with Pin1 antibody and GAPDH antibody (Cell Signaling Technology).
Co-immunoprecipitation
The inhibition of Pin1-p65 interactions was investigated using a coimmunoprecipitation assay following the manufacturer's instructions. Briefly, HeLa cells (1x10 6 cells/well) were treated with indicated concentrations of 1a (1 and 10 µM) and DMSO for 12 h. After cell lysis and protein lysate separation, 100 µg of total protein was incubated with p65 antibody at 4 °C overnight. The proteins were immunoprecipitated using agarose beads. The levels of co-precipitated Pin1 were analyzed using Western blotting.
Transfection with plasmids.
Transfection with plasmids was performed as previously. 2 Briefly, 293T cells were seed at a density of 6 × 10 5 cell in a culture dish overnight. The cells were cotransfected with recombinant plasmids pCMV6-Pin1-wild-type for 36 h in serum-free DMEM medium using TurboFect Transfection Reagent. Then, the transfected cells were treated with an indicated concentration of 1a in 1% FBS medium for 72h.
Western blotting
HeLa cells were seeded at a density of 6 × 10 5 cell in a 6-well plate overnight. Cells were treated with 1a (in 0.1% DMSO), PiB, or vehicle control in 1% FBS medium for an additional 12h. Cells were lysed, and protein samples were collected. Protein concentration was determined by BCA protein assay kit (Thermo Scientific). 30 μg of proteins samples were resolved on a 10% SDS/PAGE gel and transferred to a polvinylidene fluoride (PVDF) membrane. Blots were blocked in 5% none-fat dry milk with TBS containing 0.1% Tween-20 for 1 h, the membranes were subsequently treated with primary antibodies to p65, phospho-p65(Thr254), Erk1/2, c-Jun, PKM2, Histone H3 and GAPDH with gentle agitation overnight at 4 °C. Then, membranes were washed five time with TBST. After incubation with secondary antibody for 1 h. Proteins bands were detected using enhanced chemiluminescent Plus reagents (GE Healthcare) and analyzed by Image Lab.
Knockdown assay
HeLa cells were seeded in 6-well plates at 80% confluence in DMEM medium for 24 h. Lipo2000 reagent and Pin1 siRNA was gently mixed and incubated for 20 min at room temperature. Then, 500 µL of the Lipo2000/siRNA mixture were added to each well. Cells were incubated at 37 °C in a CO 2 incubator for 48 h post-transfection before further research.
Half-life assay
After treated with 1a for 12h, HeLa cells were treated with 50 μg/ml cycloheximide (CHX, Sigma-Aldrich) for the indicated time periods. p65 levels were determined by Western blot analysis and quantified by densitometry analysis.
Cytotoxicity assay
HeLa, 293T and LO2 cells were seeded at 5,000 cells per well in 96-well plates and incubated overnight at 37 °C. The cells were treated with 1a at final concentration from 0.1 to 100 μM for 72 h. Then MTT reagent was added to each well at a final concentration of 0.5 mg/mL for a further 4 h. After then, the medium was replaced with 100 μL DMSO. The viability of the cells was measured by recording the absorbance of each well at 490 nm using a SpectraMax M5 microplate reader after shaking the plate for 10 min at room temperature in the dark.
Cell imaging
HeLa cells were seeded into a glass-bottomed dish (35 mm dish with 20 mm wells) for 24 h, then the cells were incubated with doxorubicin in the presence or absence of 1a for the indicated time periods or concentrations and then washed with phosphate-buffered saline three times. The luminescence imaging of complexes in cells was carried out by a Leica TCS SP8 confocal laser scanning microscope system. The excitation wavelength was 488 nm.
Flow cytometry analysis
HeLa cells were seeded at density of 1 × 10 6 in a 6-well plate, and were treated with 1a (50 μM) for 6 h and then in the presence or absence of doxorubicin (5 μM) for 6 h at 37 °C. Cells were harvested and washed twice with ice-cold PBS, and then resuspended in 1× binding buffer. The samples were immediately analyzed by flow cytometry using a C6 Flow Cytometer™ system (BD Biosciences). At least 2 × 10 5 cells were analyzed for each sample. Doxorubicin was determined by fluorescence (488 nm excitation and 585 nm emission). Data were analyzed using FlowJo7.6 software.
Data analysis
All data were reported as the means of at least three separate experiments. Group comparisons between the control group and various drug treatment groups were done by a one-way ANOVA using GraphPad Prism software (Prism). Figure S1 . 1 
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